ClinicalTrials.gg
RecruitingNCT07285018NP07Updated Nov 4, 2026

A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain

A Phase 2 interventional study of LY4065967 and Placebo in Diabetic Peripheral Neuropathic Pain, sponsored by Eli Lilly and Company. Recruiting at 36 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Nov 4, 20261 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 291 studies in Neuralgia with a site in United States — 50 open to participants now, 61 under way, 5 of them phase 3. Neuralgia · United States.

Planned enrollment
48th of 261
150 · median 40
Started
2026
with 15 others
Phase 2
78 of 291
5 open now
Primary completion
2027-07
later than 34 of 60 live
Registered
279th of 291
by date
Lead sponsor
6 of 291
Eli Lilly and Company

Among the 291 studies in Neuralgia with a site in United States, this one is the 48th largest by planned enrollment of the 261 interventional ones that give a count, is one of 16 that started in 2026, is one of 78 in phase 2, reaches primary completion later than 34 of the 60 other live ones, and was the 279th registered.

Neuralgia

1,102 studies on the registry are indexed under Neuralgia; 242 are open to participants now.

Browse Neuralgia studies →

Open to participants now

50 of the 291 studies in Neuralgia with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 50 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 153 Neuralgia studies recruiting now, 77 (50%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 291 studies in Neuralgia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to test the safety and efficacy of study drug LY4065967 for the treatment of diabetic peripheral neuropathic pain (DPNP). This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chronic pain.

03

Conditions studied

  • Diabetic Peripheral Neuropathic Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have presence of diabetic peripheral neuropathy, of symmetrical nature and in lower extremities for ≥6 months and diagnosed by a score of Part B ≥3 on Michigan Neuropathy Screening Instrument (©University of Michigan)
  • Have a history and current diagnosis of type 1 or type 2 diabetes mellitus.
  • Have an \<11% and on a stable regimen for treatment of diabetes at least 90 days prior to screening
  • Have a at screening of ≤40 kilogram per meter squared (kg/m2)

Exclusion criteria

Exclusion Criteria:

  • Are pregnant or breastfeeding
  • Have a history of other potentially causative and/or confounding sources of pain that may impair self-assessment of pain due to diabetic peripheral neuropathic pain (DPNP)
  • Have lower limb amputation due to diabetes inclusive of great toe (metatarsal bone)
  • Have serum vitamin B12 ≤200 picogram per milliliter (pg/mL)
  • Have an abnormal BP (systolic BP >140 mm Hg and diastolic BP>90 mm Hg) at screening
  • Have history or current cardiac disease, including arrhythmia, aortic aneurysm, heart failure, current electrolyte abnormalities, or any other conditions that could predispose to arrhythmia in the judgement of the investigator
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    LY4065967

    Participants will receive LY4065967 orally.

    Drug: LY4065967

  • Placebo comparator
    Placebo

    Participants will receive placebo orally.

    Drug: Placebo

Interventions

  • Administered orally

  • DrugPlacebo

    Administered orally

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)

    Time frame: Baseline, Week 8

Secondary outcomes

  1. Change From Baseline in the Brief Pain Inventory-Short Form Modified (BPI-SFM) Total Pain Interference Score

    Time frame: Baseline, Week 8

  2. Change from Baseline in Overall Improvement as Measured by Patient's Global Impression of Change (PGI-C)

    Time frame: Baseline, Week 8

  3. Change from Baseline in Worst Pain Intensity as Measured by NRS

    Time frame: Baseline, Week 8

  4. Change from Baseline in Sleep Scale from the Medical Outcomes Study (MOS Sleep Scale)

    Time frame: Baseline, Week 8

  5. Change from Baseline in Emotional Functioning as Measured by the EuroQol-5D 5 Level Questionnaire (EQ 5D 5L)

    Time frame: Baseline, Week 8

  6. Total Amount of Rescue Medication Used Daily During the Treatment Phase

    Time frame: Week 8

07

Study locations

36 of 36 sites recruiting
  • Central Research Associates
    Birmingham, Alabama 35205, United States
    Recruiting
    • David DeAtkine · Principal investigator
  • Synexus Clinical Research US, Inc.
    Phoenix, Arizona 85020, United States
    Recruiting
    • Shawn Searle · Principal investigator
  • Arizona Research Center
    Phoenix, Arizona 85053, United States
    Recruiting
    • Louise Taber MD · Principal investigator
  • Desert Oasis Healthcare Medical Group
    Palm Springs, California 92262, United States
    Recruiting
    • Michael Jardula · Principal investigator
  • Artemis Institute for Clinical Research
    Riverside, California 92503, United States
    Recruiting
    • Jack Vu · Principal investigator
  • Artemis Institute for Clinical Research
    San Diego, California 92123, United States
    Recruiting
    • Stacey Layle · Principal investigator
  • CMR of Greater New Haven
    Hamden, Connecticut 06517, United States
    Recruiting
    • Joseph Soufer · Principal investigator
  • Bradenton Research Center, Inc.
    Bradenton, Florida 34205, United States
    Recruiting
    • Eric Folkens · Principal investigator
  • Accel Research Sites - DeLand Clinical Research Unit
    DeLand, Florida 32720, United States
    Recruiting
    • Bruce Rankin · Principal investigator
  • K2 MEDICAL Research THE VILLAGES
    Lady Lake, Florida 32159, United States
    Recruiting
    • Craig Curtis · Principal investigator
  • K2 Medical Research ORLANDO
    Maitland, Florida 32751, United States
    Recruiting
    • Brandon Lenox · Principal investigator
  • Merritt Island Medical Research, LLC
    Merritt Island, Florida 32952, United States
    Recruiting
    • David Kirk · Principal investigator
  • Suncoast Research Group
    Miami, Florida 33135, United States
    Recruiting
    • Mark Kutner · Principal investigator
  • New Horizon Research Center
    Miami, Florida 33165, United States
    Recruiting
    • Lazaro Nunez · Principal investigator
  • Suncoast Clinical Research, Inc.
    New Port Richey, Florida 34652, United States
    Recruiting
    • Cathy Barnes · Principal investigator
  • Renstar Medical Research
    Ocala, Florida 34470, United States
    Recruiting
    • David Oliver · Principal investigator
  • Precision Clinical Research
    Sunrise, Florida 33351, United States
    Recruiting
    • Richard Linn · Principal investigator
  • Charter Research - Lady Lake
    The Villages, Florida 32162, United States
    Recruiting
    • Stephen Miller · Principal investigator
  • Conquest Research
    Winter Park, Florida 32789, United States
    Recruiting
    • Anand Patel · Principal investigator
  • North Georgia Clinical Research
    Woodstock, Georgia 30189, United States
    Recruiting
    • · Contact678-494-5735
    • Bram Wieskopf · Principal investigator
  • Northwestern University
    Chicago, Illinois 60611, United States
    Recruiting
    • Thomas Schnitzer · Principal investigator
  • DelRicht Research
    New Orleans, Louisiana 70115, United States
    Recruiting
    • Patrick Dennis · Principal investigator
  • Lucida Clinical Trials
    New Bedford, Massachusetts 02740, United States
    Recruiting
    • David Shih · Principal investigator
  • MedVadis Research Corporation
    Waltham, Massachusetts 02451, United States
    Recruiting
    • David DiBenedetto · Principal investigator
  • Great Lakes Research Group, Inc.
    Bay City, Michigan 48706, United States
    Recruiting
    • Jeffrey Potts · Principal investigator
  • StudyMetrix Research
    City of Saint Peters, Missouri 63303, United States
    Recruiting
    • Timothy Smith · Principal investigator
  • Clinvest Research LLC
    Springfield, Missouri 65807, United States
    Recruiting
    • Ralph Duda · Principal investigator
  • Rochester Clinical Research, LLC
    Rochester, New York 14609, United States
    Recruiting
    • Patrick Connors · Principal investigator
  • Lillestol Research
    Fargo, North Dakota 58104, United States
    Recruiting
    • Michael Lillestol · Principal investigator
  • META Medical Research Institute
    Dayton, Ohio 45432, United States
    Recruiting
    • Priyesh Mehta · Principal investigator
  • DelRicht Research
    Tulsa, Oklahoma 74133, United States
    Recruiting
    • Melita Tate · Principal investigator
  • Altoona Center For Clinical Research
    Duncansville, Pennsylvania 16635, United States
    Recruiting
    • Alan Kivitz · Principal investigator
  • FutureSearch Trials of Neurology
    Austin, Texas 78731, United States
    Recruiting
    • John Hudson · Principal investigator
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
    Recruiting
    • Arifulla Khan, MD · Principal investigator
  • Rainier Clinical Research Center
    Renton, Washington 98057, United States
    Recruiting
    • Sheryl Marks · Principal investigator
  • Ponce Medical School Foundation Inc.
    Ponce, 00716, Puerto Rico
    Recruiting
    • Elizabeth Barranco-Santana · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jul 2027, 17 months after the start.

Of 34 industry-sponsored phase 2 interventional studies under Neuralgia, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 22. This study's planned 17 months is above that.

Counting every sponsor, half of 58 studies reached it within 22 months; a quarter within 11 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2025
First posted
Dec 16, 2025
StartActual
Feb 16, 2026
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site removed
Show 1 removed
  • Re:Cognition Health - Fort Worth · Fort Worth, United States
Nov 4, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • North Georgia Clinical Research · Woodstock, United StatesContact added •••5735
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    1 site removed
    Show 1 removed
    • Re:Cognition Health - Fort Worth · Fort Worth, United States
    Site contacts Changed at 1 site. See the sites
    Show the site
    • North Georgia Clinical Research · Woodstock, United StatesContact added •••5735
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07285018
Responsible party
Sponsor
First posted
Dec 16, 2025
Start date
Feb 16, 2026
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LY4065967

Start the discussion